Luigi Ricciardiello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8410934/publications.pdf

Version: 2024-02-01

100 papers

4,607 citations

36 h-index 65 g-index

106 all docs

106 docs citations

106 times ranked 7101 citing authors

#	Article	IF	CITATIONS
1	Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 58-59, 101793.	1.0	16
2	Digestive cancer screening across Europe. United European Gastroenterology Journal, 2022, 10, 435-437.	1.6	8
3	Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer. Cancers, 2022, 14, 2231.	1.7	7
4	Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality. Clinical Gastroenterology and Hepatology, 2021, 19, 1410-1417.e9.	2.4	90
5	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. Gut, 2021, 70, 1241-1243.	6.1	8
6	Colorectal polyposis as a clue to the diagnosis of Cowden syndrome: Report of two cases and literature review. Pathology Research and Practice, 2021, 218, 153339.	1.0	8
7	Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. BMJ Open Gastroenterology, 2021, 8, e000578.	1.1	49
8	Gastric Melanoma of Unknown Primary. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 14-14.	0.5	2
9	The Roadmap of Colorectal Cancer Screening. Cancers, 2021, 13, 1101.	1.7	28
10	The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Diagnostics, 2021, 11, 795.	1.3	19
11	Discovering the Mutational Profile of Early Colorectal Lesions: A Translational Impact. Cancers, 2021, 13, 2081.	1.7	2
12	Unveiling the Correlation between Inadequate Energy/Macronutrient Intake and Clinical Alterations in Volunteers at Risk of Metabolic Syndrome by a Predictive Model. Nutrients, 2021, 13, 1377.	1.7	3
13	Horizon Europe, the new programme for research \hat{A} amp; innovation: Which opportunities for GI research in the years to come?. United European Gastroenterology Journal, 2021, 9, 407-409.	1.6	6
14	Systematic review with metaâ€analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2021, 54, 14-23.	1.9	20
15	Impairment of colorectal cancer screening during the COVID-19 pandemic. The Lancet Gastroenterology and Hepatology, 2021, 6, 425-426.	3.7	3
16	Changes in digestive cancer diagnosis during the SARS-CoV-2 pandemic in Italy: A nationwide survey. Digestive and Liver Disease, 2021, 53, 682-688.	0.4	30
17	Editorial: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer—Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 506-507.	1.9	2
18	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterology Journal, 2021, 9, 860-871.	1.6	28

#	Article	IF	CITATIONS
19	COVIDâ€19 and digestive health: Implications for prevention, care and the use of COVIDâ€19 vaccines in vulnerable patients. United European Gastroenterology Journal, 2021, 9, 1091-1095.	1.6	8
20	DHA-Induced Perturbation of Human Serum Metabolome. Role of the Food Matrix and Co-Administration of Oat β-glucan and Anthocyanins. Nutrients, 2020, 12, 86.	1.7	7
21	The changing approach for identifying hereditary colorectal cancer syndromes. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 593-594.	8.2	3
22	Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection. Medical Hypotheses, 2020, 143, 110095.	0.8	1
23	COVID-19: Don't Neglect the Gastrointestinal Tract!. Digestive Diseases, 2020, 38, 259-260.	0.8	4
24	Are Wnt/ \hat{l}^2 -Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 491-506.	2.3	69
25	Hospital admission for digestive diseases: Gastroenterology units offer a more effective and efficient care. Digestive and Liver Disease, 2019, 51, 43-46.	0.4	3
26	A Dietary Intervention of Bioactive Enriched Foods Aimed at Adults at Risk of Metabolic Syndrome: Protocol and Results from PATHWAY-27 Pilot Study. Nutrients, 2019, 11, 1814.	1.7	21
27	Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 877-895.	1.0	157
28	Future research demands of the United European Gastroenterology (UEG) and its member societies. United European Gastroenterology Journal, 2019, 7, 859-863.	1.6	2
29	Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 1082-1093.	1.0	80
30	Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial. Trials, 2019, 20, 327.	0.7	17
31	A Mediterranean Diet Mix Has Chemopreventive Effects in a Murine Model of Colorectal Cancer Modulating Apoptosis and the Gut Microbiota. Frontiers in Oncology, 2019, 9, 140.	1.3	26
32	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. Cancer Immunology Research, 2019, 7, 751-758.	1.6	29
33	Diagnostic yield and miss rate of EndoRings in an organized colorectal cancer screening program: the SMART (Study Methodology for ADR-Related Technology) trial. Gastrointestinal Endoscopy, 2019, 89, 583-590.e1.	0.5	25
34	Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. Digestive Diseases and Sciences, 2019, 64, 863-874.	1.1	8
35	A PREDICTIVE MODEL IDENTIFIES PATIENTS LESS LIKELY TO HAVE ADENOMAS AFTER A COLON CANCER. , 2019, 51, .		O
36	Somatic APC mosaicism and oligogenic inheritance in genetically unsolved colorectal adenomatous polyposis patients. European Journal of Human Genetics, 2018, 26, 387-395.	1.4	26

#	Article	IF	CITATIONS
37	LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancerâ€"Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result. Clinical Colorectal Cancer, 2018, 17, e217-e228.	1.0	24
38	miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4. Molecular Cancer Research, 2018, 16, 1965-1976.	1.5	17
39	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. Frontiers in Immunology, 2018, 9, 1039.	2.2	6
40	Lifestyle factors and risk for colorectal polyps and cancer at index colonoscopy in a FITâ€positive screening population. United European Gastroenterology Journal, 2018, 6, 935-942.	1.6	15
41	Prevalence of serrated polyposis syndrome in an FIT-based colorectal cancer screening cohort in Italy. Gut, 2017, 66, 1532-1533.	6.1	6
42	Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Scientific Reports, 2017, 7, 7458.	1.6	54
43	Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials. Current Colorectal Cancer Reports, 2017, 13, 192-204.	1.0	0
44	Inflammation and Notch signaling: a crosstalk with opposite effects on tumorigenesis. Cell Death and Disease, 2016, 7, e2515-e2515.	2.7	63
45	Inflammation increases NOTCH1 activity via MMP9 and is counteracted by Eicosapentaenoic Acid-free fatty acid in colon cancer cells. Scientific Reports, 2016, 6, 20670.	1.6	43
46	Chemoprevention of hereditary colon cancers: time for new strategies. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 352-361.	8.2	62
47	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	0.5	30
48	Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis. Scandinavian Journal of Gastroenterology, 2015, 50, 1382-1388.	0.6	19
49	A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 2015, 35, S151-S184.	4.3	95
50	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
51	A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. Carcinogenesis, 2014, 35, 2314-2320.	1.3	25
52	Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitisâ€associated colorectal cancer acting on Notch signaling and gut microbiota. International Journal of Cancer, 2014, 135, 2004-2013.	2.3	73
53	Mechanisms of Obesity-Induced Gastrointestinal Neoplasia. Gastroenterology, 2014, 146, 357-373.	0.6	157
54	Components of the Mediterranean Diet with chemopreventive activity toward colorectal cancer. Phytochemistry Reviews, 2014, 13, 867-879.	3.1	7

#	Article	IF	Citations
55	Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention. International Journal of Molecular Sciences, 2013, 14, 16365-16385.	1.8	354
56	Narrow Band Imaging with Magnification Endoscopy for Celiac Disease: Results from a Prospective, Single-Center Study. Diagnostic and Therapeutic Endoscopy, 2013, 2013, 1-6.	1.5	20
57	Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers. British Journal of Cancer, 2013, 108, 1750-1756.	2.9	16
58	Epigenetic silencing of Notch signaling in gastrointestinal cancers. Cell Cycle, 2012, 11, 4323-4327.	1.3	24
59	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection. Gastroenterology, 2012, 143, 55-61.e1.	0.6	81
60	Phytochemicals and colorectal cancer preventionâ€"myth or reality?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 592-596.	8.2	35
61	Chemoprevention of colorectal cancer: A role for ursodeoxycholic acid, folate and hormone replacement treatment?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 555-568.	1.0	19
62	Lethal nature of ischemic gastropathy: a case report of celiomesenteric vascular insufficiency. Clinical Journal of Gastroenterology, 2011, 4, 60-63.	0.4	2
63	Chemoprevention of Intestinal Polyps in ApcMin/+ Mice Fed with Western or Balanced Diets by Drinking Annurca Apple Polyphenol Extract. Cancer Prevention Research, 2011, 4, 907-915.	0.7	54
64	Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget, 2011, 2, 1291-1301.	0.8	59
65	Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice. Clinical Cancer Research, 2010, 16, 5703-5711.	3.2	70
66	Chronic Intestinal Pseudo-Obstruction Related to Viral Infections. Transplantation Proceedings, 2010, 42, 9-14.	0.3	41
67	JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut, 2009, 58, 25-32.	6.1	70
68	The role of viral and bacterial pathogens in gastrointestinal cancer. Journal of Cellular Physiology, 2008, 216, 378-388.	2.0	46
69	JC Virus Infection in Colorectal Neoplasia That Develops after Liver Transplantation. Clinical Cancer Research, 2008, 14, 6717-6721.	3.2	29
70	Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM–p53 cascade in colon cancer cell lines. Carcinogenesis, 2008, 29, 139-146.	1.3	118
71	Annurca Apple Polyphenols Have Potent Demethylating Activity and Can Reactivate Silenced Tumor Suppressor Genes in Colorectal Cancer Cells ,. Journal of Nutrition, 2007, 137, 2622-2628.	1.3	95
72	DNA tumor viruses and colorectal cancer. Current Colorectal Cancer Reports, 2007, 3, 76-81.	1.0	1

#	Article	IF	CITATIONS
73	Association of JC Virus T-Antigen Expression With the Methylator Phenotype in Sporadic Colorectal Cancers. Gastroenterology, 2006, 130, 1950-1961.	0.6	97
74	Lynch syndrome (hereditary non-polyposis colorectal cancer): Current concepts and approaches to management. Current Gastroenterology Reports, 2005, 7, 412-420.	1.1	13
75	High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies. Clinical Cancer Research, 2005, 11, 4234-4240.	3.2	56
76	Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine, 2005, 30, 293-302.	1.4	58
77	Measuring dyspepsia: a new severity index validated in Bologna. Digestive and Liver Disease, 2004, 36, 806-810.	0.4	19
78	JC virus and human colon carcinoma: An intriguing and inconclusive association. Gastroenterology, 2003, 124, 268-269.	0.6	19
79	Effect of H2O2 on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines. Cancer Letters, 2003, 195, 243-251.	3.2	36
80	A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clinical Cancer Research, 2003, 9, 383-90.	3.2	120
81	Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Research, 2003, 63, 1608-14.	0.4	208
82	Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Research, 2003, 63, 7256-62.	0.4	97
83	Helicobacter pylori and functional dyspepsia: review of previous studies and commentary on new data. Gut, 2002, 50, iv33-iv35.	6.1	14
84	36 OP Loss of HMLH1 due to promoter hypermethylation causes high frequency of microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Digestive and Liver Disease, 2002, 34, A72.	0.4	8
85	Chemoprevention in Colorectal Neoplasias: What Is Practical and Feasible?. Digestive Diseases, 2002, 20, 70-72.	0.8	5
86	Oxidative stress inactivates the human DNA mismatch repair system. American Journal of Physiology - Cell Physiology, 2002, 283, C148-C154.	2.1	234
87	The Role of Genomic Instabilities in Affecting Treatment Responses of Colorectal Cancer. Digestive Diseases, 2002, 20, 73-80.	0.8	1
88	Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 153-158.	1.9	21
89	The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by 13 C-urea breath test and associated factors. Alimentary Pharmacology and Therapeutics, 2001, 15, 1001-1007.	1.9	37
90	Incidence and Recurrence Rates of Colorectal Adenomas in First-Degree Asymptomatic Relatives of Patients With Colon Cancer. American Journal of Gastroenterology, 2001, 96, 1601-1604.	0.2	35

#	Article	IF	CITATIONS
91	Mad-1 Is the Exclusive JC Virus Strain Present in the Human Colon, and Its Transcriptional Control Region Has a Deleted 98-Base-Pair Sequence in Colon Cancer Tissues. Journal of Virology, 2001, 75, 1996-2001.	1.5	99
92	Steady-state Regulation of the Human DNA Mismatch Repair System. Journal of Biological Chemistry, 2000, 275, 18424-18431.	1.6	175
93	JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology, 2000, 119, 1228-1235.	0.6	152
94	How many mutations does it take to make a tumor?. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14675-14677.	3.3	78
95	Helicobacter pylori: Optimum Diagnosis and Test of Cure. Journal of Chemotherapy, 1999, 11, 601-605.	0.7	4
96	Efficacy of Lansoprazole in Eradicating Helicobacter pylori : A Metaâ€Analysis. Helicobacter, 1998, 3, 195-201.	1.6	34
97	Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Alimentary Pharmacology and Therapeutics, 1998, 12, 439-445.	1.9	57
98	Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Alimentary Pharmacology and Therapeutics, 1998, 12, 533-537.	1.9	10
99	A comparative trial to optimize the protocol of the 13C urea breath test for the diagnosis of Helicobacter pylori infection. Gastroenterology, 1998, 114, A344.	0.6	2
100	Urea Breath Tests for the Detection of Helicobacter pylori Infection. Helicobacter, 1997, 2, 34-37.	1.6	49